Develops antibodies for autoimmune diseases like alopecia areata.
Dec 2025Revenue $53.7M/yrExpenses $36.8M/yr
Reached break-even Oct 2025
Figures by year
When did Q32 Bio become profitable?
Its revenue passed its expenses in Oct 2025. In the 12 months to Dec 2025, revenue was $53.7M and expenses $36.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $53.7M | $36.8M | $16.9M |
| Dec 2024 | $0.00 | $66.1M | −$66.1M |
| Dec 2023 | −$6.65M | $41.6M | −$48.3M |
| Dec 2022 | $3.21M | $136M | −$133M |
| Dec 2021 | $34.0M | $130M | −$95.9M |
| Dec 2020 | $2.70M | $133M | −$130M |
| Dec 2019 | $1.67M | $112M | −$110M |
| Dec 2018 | $3.68M | $63.6M | −$59.9M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.